Bernhard R. M. Ehmer
Président chez BIOTEST AG
Fortune : 87 025 $ au 30/04/2024
Postes actifs de Bernhard R. M. Ehmer
Sociétés | Poste | Début | Fin |
---|---|---|---|
AFFIMED N.V. | Directeur/Membre du Conseil | 21/01/2016 | - |
Independent Dir/Board Member | 21/01/2016 | - | |
ACHILLES THERAPEUTICS PLC | Directeur/Membre du Conseil | 04/05/2022 | - |
Independent Dir/Board Member | 04/05/2022 | - | |
BIOTEST AG | Président | 05/05/2022 | - |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Directeur/Membre du Conseil | 01/01/2016 | - |
Historique de carrière de Bernhard R. M. Ehmer
Anciens postes connus de Bernhard R. M. Ehmer
Sociétés | Poste | Début | Fin |
---|---|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Président | 01/09/2018 | 01/06/2020 |
BIOTEST AG | Directeur Général | 01/01/2015 | 01/04/2019 |
ADMA BIOLOGICS, INC. | Directeur/Membre du Conseil | 06/06/2017 | 15/02/2018 |
ImClone Systems Corp. | President | 01/11/2009 | 01/10/2014 |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Corporate Officer/Principal | 01/01/2008 | 01/01/2012 |
░░░░░░ ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formation de Bernhard R. M. Ehmer
Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Statistiques
Internationale
Allemagne | 11 |
Etats-Unis | 4 |
France | 2 |
Opérationnelle
Director/Board Member | 5 |
Chief Executive Officer | 3 |
President | 3 |
Sectorielle
Health Technology | 12 |
Consumer Services | 3 |
Commercial Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 6 |
---|---|
ATON | Health Technology |
ADMA BIOLOGICS, INC. | Health Technology |
MERCK KGAA | Health Technology |
BIOTEST AG | Health Technology |
AFFIMED N.V. | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Entreprise privées | 8 |
---|---|
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |
BioPheresis Technologies, Inc.
BioPheresis Technologies, Inc. Medical SpecialtiesHealth Technology BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA. | Health Technology |
ImClone Systems Corp. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Health Technology |
Biopheresis GmbH
Biopheresis GmbH Miscellaneous Commercial ServicesCommercial Services Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The private company is based in Heidelberg, Germany. | Commercial Services |
Boehringer Mannheim GmbH |
- Bourse
- Insiders
- Bernhard R. M. Ehmer
- Expérience